Synergistic Effects of Serum Uric Acid and Cardiometabolic Risk Factors on Early Stage Atherosclerosis: The Cardiometabolic Risk in Chinese Study

Citation
Liang, Jun, Yanping Li, Na Zhou, Fei Teng, Jing Zhao, Caiyan Zou, and Lu Qi. 2012. Synergistic effects of serum uric acid and cardiometabolic risk factors on early stage atherosclerosis: The cardiometabolic risk in Chinese study. PLoS ONE 7(12): e51101.

Published Version
doi:10.1371/journal.pone.0051101

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10613628

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Synergistic Effects of Serum Uric Acid and Cardiometabolic Risk Factors on Early Stage Atherosclerosis: The Cardiometabolic Risk in Chinese Study

Jun Liang1,2*, Yanping Li3*, Na Zhou4*, Fei Teng1, Jing Zhao1, Caiyan Zou1, Lu Qi2,3*

1 Department of Endocrinology, the Central Hospital of Xuzhou, Xuzhou Clinical School of Xuzhou Medical College, Affiliated Hospital of Southeast University, Xuzhou, Jiangsu, People’s Republic of China, 2 Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America, 3 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 4 Oriental People’s Hospital of Xuzhou, Xuzhou, Jiangsu, People’s Republic of China

Abstract

Objective: To comprehensively examine the associations of serum uric acid (SUA) with central and peripheral arterial stiffness in Chinese adults, and particularly assess the interactions between SUA and other cardiometabolic risk factors.

Methods: The study included 3,772 Chinese men and women with carotid radial pulse wave velocity (crPWV), carotid femoral PWV (cfPWV), carotid artery dorsalis pedis PWV (cdPWV) and SUA measured.

Results: After adjustment for age, sex, and BMI, the levels of SUA were significantly associated with increasing trend of cfPWV, crPWV and cdPWV (P for trend <0.0001). Further adjustment for heart rate (HR), blood pressure (BP) and lipids attenuated the associations with crPWV and cdPWV to be non-significant (P = 0.1, P = 0.099 respectively), but the association between SUV and cfPWV remained significant (P = 0.004). We found significant interactions between SUA and HR or BP in relation to cfPWV (P for interaction = 0.03, 0.003 respectively). The associations between SUA and cfPWV were more evident among individuals with higher HR or normal BP than those with lower HR or hypertension.

Conclusions: SUA was associated with elevated aortic arterial stiffness in Chinese adults, independent of conventional cardiovascular risk factors. BP and HR might modify the deleterious effects of SUA.

Introduction

Serum uric acid (SUA) is a final enzymatic product of purine metabolism in humans. In clinical and epidemiological studies, SUA has been related to the risk of hypertension [1–3], atherosclerosis [4] and cardiovascular diseases (CVDs) [5,6]. The adverse effects of SUA may occur at early stage of atherosclerosis [7,8]. Pulse wave velocity (PWV) is a gold standard for assessing arterial stiffness and widely used indicator for early atherosclerosis [9,10], and PWVs at different sites may reflect the atherosclerotic alterations at central (e.g. cfPWV) or peripheral arteries (e.g. cdPWV and crPWV). Few studies have comprehensively compared the effects of circulating SUA on these various measures.

In addition, it has been documented that both blood SUA levels and arterial stiffness are tightly related to other cardiometabolic risk factors such as high heart rate (HR) or blood pressure (BP) [2,3,11,12]. However, few studies have examined the potential interactions between SUA and those factors. It remains to be determined whether other cardiometabolic risk factors may modify the cardiovascular effects of SUA.

In the present study of a large sample of Chinese adults, we sought to comprehensively evaluate the effects of SUA on peripheral and central arterial stiffness. We particularly assessed whether blood pressure, heart rate, and other cardiometabolic risk factors may modify the relation between SUA and arterial stiffness.

Methods

1. Study Population

In the Cardiometabolic Risk in Chinese (CRC) Study, we performed a community-based health examination survey for subjects (18–93 y) who were randomly selected from residents...
living in the urban area of Xuzhou, China, in 2009. Written consents were obtained from all the participants. The study was reviewed and approved by the ethics committee of the Central Hospital of Xuzhou, Affiliated Hospital of Medical School of Southeast University, China. For the present study, we included adult men and women (≥18 y) who were successfully measured for PWVs, BP, Body mass index (BMI), HR, SUA and other metabolic markers. The exclusion criteria included the history of vascular disease, diabetes mellitus, or hyperlipidemia which was being treated with medication, and renal failure (GFR reduced to 10–20% and serum creatinine elevated to 451–707 umol/L) [13]. In addition, we excluded people who did not undergo PWV determination or omitted blood sampling. In total, 3,772 men and women were included in the final analyses. There was not significant difference in basic characteristics such as age, education, and anthropometrics between individuals included in the analyses and those who were excluded.

2. Assessment of PWVs

All measurements were performed in a quiet room with controlled ambient temperature. The cPWV was measured in the supine position after 5 min of bed rest using an automatic waveform analyzer (Complior System, Artech-Medical corp, French), the pulse wave of the carotid and femoral arteries was analyzed, estimating the delay with respect to the ECG wave and calculating the PWV. cdPWV and crPWV were obtained in a similar way, with the pulse wave being measured simultaneously in the right radial, dorsal of foot and right carotid arteries. 16 consecutive electrocardiogram gated waveforms were obtained and removed the three maximum and three minimum. For analysis, we averaged 10 waveforms. PWV was based on the distance/time ratio (meters/second), was calculated as the path length divided by the transit time and expressed as m/s [14].

3. Assessment of Biomarkers and covariates

All the participants were measured biomarkers. Venous blood sample was drawn from all subjects after an overnight fast (8–12 h). After blood was drawn, samples were allowed to clot at room temperature for 1–3 h and serum was separated. Immediately after clotting, serum was separated by centrifugation for 15 min at 3000 r.p.m. Fasting blood samples were collected for measurement of glucose, SUA, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). All biochemical assays were determined enzymatically on an auto analyzer (Type 7600, Hitachi Ltd, and Tokyo, Japan). Height was measured to the nearest 0.5 cm without shoes and body weight was measured to the nearest 100 grams without shoes. BMI was calculated as weight (in kilograms) divided by height (in meters) squared. BP was measured after the subject had rested for at least 5 minutes with a mercury manometer by doctors. The mean arterial pressure (MAP) was calculated as 2/3(Diastolic blood pressure, DBP)+1/3(Systolic blood pressure, SBP). Three measurements, 60 seconds apart, were taken. The mean of the three measurements was used for analysis. Information of education level, income smoking status and alcohol consumption was collected using a questionnaire.

4. Statistical Analysis

The relations between SUA levels (in quartiles) and PWVs were examined using general linear regression models, adjusting for covariates including age, sex, BMI, HR, fasting glucose, lipid profiles and BP. SUA and TG levels were log-transformed to improve normal distribution before analysis. The interactions between SUA and other cardiometabolic risk factors were assessed by introduction of cross-product term in the regression models. All reported P values are two tailed. Variables with P values of <0.05 were considered statistically significant. Data management and statistical analysis were conducted using SAS statistical software (version 9.1; SAS Institute, Inc., Cary, NC, USA).

Results

1. The characteristics of the study participants by SUA levels

The average age of study population was 45.4 years and was represented by 63.3% of men. Table 1 shows the characteristics of the study participants according to SUA levels (in quartiles). BMI, waist circumference, BP, glucose, insulin, TG and LDL-C showed statistically significant differences between SUA groups, with an increasing trend as the concentration of SUA increased, except for HDL-C that showed a decreasing trend.

2. Association between SUA and markers of central and peripheral arterial stiffness

Table 2 displays the associations of PWVs with SUA in quartile. After adjustment for age, sex and BMI, the levels of SUA were significantly associated with an increasing trend of cPWV, crPWV and cdPWV in a dose-dependent pattern (P for trend <0.0001). Further adjustment for HR, fasting glucose and lipids did not significantly change the associations. However, further addition of blood pressure in the models attenuated the associations with crPWV and cdPWV to be not significant (P=0.1, P=0.099 respectively); while the association between SUV and cPWV remained significant (P=0.004). Additional adjustment of education level, income, smoking and alcohol consumption did not appreciably change the results.

3. Stratified associations by cardiometabolic risk factors

We found significant interaction between age and SUA level in relation to cPWV (P for interaction <0.001). Table 3 shows the significant interactions of SUA with age, sex, BMI, HR, fasting glucose, lipids and BP. Further adjustment for age, sex, BMI, fasting glucose, lipids and BP, we found that the association between SUA and cPWV was different in three HR groups (P for interaction = 0.03). The associations were stronger in individuals with HR of 65–75 bpm (P=0.007 and ≥75 bpm (P=0.007) than those with HR<65 bpm (P=0.11). In addition, we found significant interaction between hypertension status and SUA level in relation to cPWV, adjusted for age, sex, BMI, fasting glucose, lipids and HR (P for interaction = 0.003). The associations between SUA and cPWV were significant (P<0.0001) among those with normal blood pressure, but not significant among those with hypertension.

Discussion

In the present study of a large sample of Chinese adults, we found that SUA levels were significantly related to central arterial stiffness independent of conventional risk factors, such as sex, BMI, lipids, glucose metabolism. SUA levels were not associated with peripheral arterial stiffness, measured by crPWV and cdPWV. Moreover, we found significant interactions between SUA and HR or BP in relation to cPWV.
### Table 1. Characteristics of the participants by serum uric acid (SUA) levels.

| Variables                  | Q1 (≤238, N = 941) | Q2 (238–294.4, N = 943) | Q3 (294.4–348.9, N = 946) | Q4 (≥348.9, N = 942) | for trend |
|----------------------------|---------------------|--------------------------|---------------------------|----------------------|-----------|
| cPWV (m/s)                 | 9.83 ± 0.05         | 10.39 ± 0.06             | 10.75 ± 0.06              | 11.0 ± 0.06          | 0.009     |
| cdPWV (m/s)                | 8.87 ± 0.05         | 9.56 ± 0.05              | 9.85 ± 0.06               | 10.1 ± 0.05          | 0.23      |
| cr PWV (m/s)               | 9.59 ± 0.05         | 10.27 ± 0.05             | 10.68 ± 0.06              | 11.0 ± 0.06          | 0.003     |
| Age, years                 | 45.2 ± 12.1         | 44.8 ± 11.4              | 45.1 ± 11.7               | 45.7 ± 12.4          | 0.33      |
| Men, %                     | 63.3                | 63.3                     | 63.3                      | 63.4                 | 1.00      |
| Body mass index, kg/m²     | 23.5 ± 0.1          | 24.1 ± 0.1               | 24.4 ± 0.1                | 25.8 ± 0.1           | < 0.0001  |
| Waist circumference, cm    | 83.2 ± 0.3          | 84.4 ± 0.3               | 85.7 ± 0.3                | 89.1 ± 0.3           | < 0.0001  |
| Systolic blood pressure, mmHg | 121.2 ± 0.5        | 122.5 ± 0.5              | 123.6 ± 0.5               | 127.0 ± 0.5          | < 0.0001  |
| Diastolic blood pressure, mmHg | 77.3 ± 0.4         | 78.0 ± 0.4               | 79.8 ± 0.4                | 82.1 ± 0.4           | < 0.0001  |
| Fasting glucose, mmol/L    | 4.8 ± 0.04          | 5.0 ± 0.04               | 5.1 ± 0.04                | 5.2 ± 0.04           | 0.02      |
| Fasting insulin (IU/ml)    | 7.5 ± 0.14          | 8.4 ± 0.15               | 9.0 ± 0.17                | 11.2 ± 0.24          | < 0.0001  |
| 2 h OGTT, mmol/L           | 7.48 ± 0.10         | 7.15 ± 0.10              | 7.29 ± 0.10               | 7.72 ± 0.11          | 0.03      |
| Triglyceride, mmol/L       | 1.26 ± 0.05         | 1.48 ± 0.05              | 1.65 ± 0.05               | 2.18 ± 0.05          | < 0.0001  |
| LDL-C (mmol/l)             | 2.8 ± 0.03          | 2.9 ± 0.03               | 3.0 ± 0.03                | 3.1 ± 0.03           | < 0.0001  |
| HDL-C, mmol/L              | 1.30 ± 0.01         | 1.27 ± 0.01              | 1.25 ± 0.01               | 1.20 ± 0.01          | < 0.0001  |

Abbreviations: OGTT, oral glucose tolerance test; HDL-C, high density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Data are age and sex adjusted mean ± standard error. Linear regression model was used to test trend for continuous variables; χ² test was used for the categorical variables.

**Table 2.** Associations of SUA with central and peripheral arterial stiffness.

| Models                      | SUA in quartiles | P       | for trend |
|-----------------------------|------------------|---------|-----------|
|                            | Q1 (≤238, N = 941) | Q2 (238–294.4, N = 943) | Q3 (294.4–348.9, N = 946) | Q4 (≥348.9, N = 942) |         |
| cf_PWV                      |                  |         |           |           |         |
| Crude                       | 10.39 (0.06)     | 10.44 (0.06) | 10.62 (0.06) | 10.82 (0.06) | < .0001 |
| Age and sex adjusted        | 10.39 (0.05)     | 10.46 (0.05) | 10.63 (0.05) | 10.79 (0.05) | < .0001 |
| Further adjusted for BMI    | 10.41 (0.06)     | 10.47 (0.05) | 10.63 (0.05) | 10.80 (0.06) | < .0001 |
| Further adjusted for fasting glucose, lipid profiles and heart rate | 10.48 (0.06) | 10.53 (0.06) | 10.63 (0.06) | 10.76 (0.06) | 0.0006 |
| Further adjusted for blood pressure | 10.48 (0.05) | 10.51 (0.05) | 10.65 (0.05) | 10.72 (0.05) | 0.004   |
| cd_PWV                      |                  |         |           |           |         |
| Crude                       | 9.40 (0.05)      | 9.50 (0.05)  | 9.64 (0.05)  | 9.78 (0.05)  | < .0001 |
| Age and sex adjusted        | 9.40 (0.05)      | 9.51 (0.05)  | 9.64 (0.05)  | 9.77 (0.05)  | < .0001 |
| Further adjusted for BMI    | 9.46 (0.05)      | 9.52 (0.05)  | 9.64 (0.05)  | 9.71 (0.05)  | < .0001 |
| Further adjusted for fasting glucose, lipid profiles and heart rate | 9.54 (0.05) | 9.54 (0.05)  | 9.62 (0.05)  | 9.68 (0.05)  | 0.03   |
| Further adjusted for blood pressure | 9.56 (0.05) | 9.54 (0.05)  | 9.62 (0.05)  | 9.65 (0.05)  | 0.099   |
| cr_PWV                      |                  |         |           |           |         |
| Crude                       | 10.12 (0.05)     | 10.29 (0.05) | 10.40 (0.05) | 10.39 (0.05) | < .0001 |
| Age and sex adjusted        | 10.12 (0.05)     | 10.28 (0.05) | 10.40 (0.05) | 10.39 (0.05) | < .0001 |
| Further adjusted for BMI    | 10.13 (0.05)     | 10.28 (0.05) | 10.40 (0.05) | 10.39 (0.05) | < .0001 |
| Further adjusted for fasting glucose, lipid profiles and heart rate | 10.20 (0.05) | 10.33 (0.05) | 10.40 (0.05) | 10.38 (0.05) | 0.014   |
| Further adjusted for blood pressure | 10.23 (0.05) | 10.34 (0.05) | 10.38 (0.05) | 10.35 (0.05) | 0.10   |

PWVs are presented as mean (standard error).
Several previous studies have shown that hyperuricemia was associated with cardiovascular disease [15,16], and the detrimental effects of high SUA might occur at early stage of atheroclerosis [7,8]. In a recent cross-sectional study, it was found that SUA was independently related to brachial ankle PWV (baPWV) in She ethnic minority of China [17]. However, it is not clear whether SUA levels specifically affect central or peripheral arterial stiffness because baPWV may be influenced by both sites [18]. Our results indicate that high SUA more likely affect central arterial stiffness; while its effects on peripheral arterial stiffness are modest. Notably, in the Framingham Heart Study, one standard deviation (SD) increment in arterial stiffness, as measured by cfPWV, was associated with a 48% increase in arterial disease risk, independently of conventional risk factors [19].

Intriguingly, we found the association between SUA and cfPWV was stronger among adults with higher HR ($\geq 65$). Several cohort studies have demonstrated that increased HR at rest is a significant risk factor for CVD and is a marker of new onset of atherosclerosis even in apparently healthy individuals [20,21]. Evidence has also shown that elevated HR is directly associated with risk of developing hypertension and metabolic syndrome, and is a potent predictor of cardiovascular mortality [22]. A recent prospective study found a synergistic role of high baseline HR and changes in HR during the follow-up period in accelerating

| Table 3. Stratified associations between SUA and cfPWV by sex, age and BMI. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| SUA in quartiles                | Q1              | Q2              | Q3              | Q4              | P for trend     | P for interaction |
| Age                            |                 |                 |                 |                 |                 |                 |
| <40 y; N = 1070                 | 10.00 (0.09)    | 9.95 (0.08)     | 10.07 (0.08)    | 10.13 (0.08)    | 0.18            | <0.001           |
| 40 to 59 y; N = 2347            | 10.41 (0.06)    | 10.44 (0.06)    | 10.53 (0.06)    | 10.57 (0.06)    | 0.03            |                 |
| $\geq$ 60 y; N = 355            | 12.52 (0.33)    | 13.00 (0.35)    | 13.56 (0.32)    | 13.54 (0.31)    | 0.02            |                 |
| Sex                            |                 |                 |                 |                 |                 |                 |
| Women, N = 1283                 | 9.79 (0.08)     | 9.79 (0.08)     | 9.96 (0.08)     | 10.0 (0.08)     | 0.04            | 0.65             |
| Men, N = 2389                   | 10.86 (0.07)    | 10.91 (0.07)    | 11.03 (0.07)    | 11.09 (0.07)    | 0.01            |                 |
| BMI                            |                 |                 |                 |                 |                 |                 |
| <23 kg/m2; N = 1350             | 10.07 (0.08)    | 10.44 (0.08)    | 10.39 (0.09)    | 10.40 (0.12)    | 0.008           | 0.53             |
| 23 to 24.9 kg/m2; N = 895       | 10.59 (0.11)    | 10.37 (0.10)    | 10.62 (0.10)    | 10.56 (0.11)    | 0.70            |                 |
| $\geq$ 25 kg/m2; N = 1527       | 10.92 (0.10)    | 10.62 (0.09)    | 10.89 (0.08)    | 10.98 (0.07)    | 0.11            |                 |

Analyses were adjusted for age, sex, BMI, total cholesterol, triglyceride, HDL-C, LDL-C, blood pressure, heart rate and fasting glucose but not the strata variable. cfPWV is presented as mean (standard error).
doi:10.1371/journal.pone.0051101.t003

**Figure 1. Interaction between SUA and HR in relation to cfPWV.** The predicted cfPWV by log-transformed SUA in different HR categories: $\leq 65$, 65–75 and $\geq 75$ bpm are presented. Analysis was adjusted for age, sex, BMI, fasting glucose, lipids and BP.
doi:10.1371/journal.pone.0051101.g001
increases of baPWV [12]. These findings as well as our result suggest that high SUA and high HR may synergistically affect central arterial stiffness.

Another interesting finding is that the adverse effects of SUA on central arterial stiffness appeared more evident in people with normal blood pressure than those with hypertension. Notably, on average cPWV was much higher and its variance was smaller in individuals with hypertension than those with normal blood pressure (Figure 2). Therefore, it is not surprising a null association was observed between SUA and cfPWV in hypertensive patients. Recent clinical evidence and experimental studies showed that SUA levels contribute to incident hypertension and prehypertension [2,23,24]. One prospective study showed that inflammatory and adiponectin-mediated proatherogenic activation are interrelated and interact leading to a significant increase of arterial stiffness in essential hypertensive patients [25]. Our findings suggest that high SUA levels may play a more important role in arterial stiffness before the development of hypertension. This finding might have important clinical implications for prevention and intervention of cardiovascular risk at early stage.

Our data showed a stronger effect of SUA on central arterial stiffness in older population. Shen et al. reported that cPWV increased at the early stage of carotid artery atherosclerosis in elderly patients, compared to younger subjects [26]. Elevated SUA experimentally stimulates renal vasoconstriction and activation of the renin-angiotensin system. Senior age is associated with activation of the renin-angiotensin system and with renal vasoconstriction [27]. Also increased SUA levels are accompanied by a state of pronounced inflammatory activation and hypoadiponectinemia that significantly impairs the arterial stiffness accelerating the vascular ageing process [28]. Our results suggest that older individuals may be more sensitive to the detrimental effects of high SUA on atherosclerosis.

The sample size of the present study is large, which ensures sufficient power to detect the moderate effects of SUA on arterial stiffness and interactions with other cardiometabolic risk factors. However, several limitations of this study warrant consideration. Our study is cross-sectional in design. Therefore, a causal relation between SUA and arterial stiffness could not be derived. We have carefully adjusted for the potential confounding in the analyses. However, in our study samples, we did not collect information of dietary intake and the lifestyle information is not incomplete. Therefore, it is still possible the residual confounding of these unmeasured variables might influence the associations. In addition, the study was performed in a Chinese population. Further studies in other populations of different ethnicities are warranted to verify our findings.

Conclusion

In conclusion, in Chinese adults we found that SUA was associated with elevated aortic arterial stiffness, independent of conventional cardiovascular risk factors. BP and HR might modify the deleterious effects of SUA. Our data lend support of the role of SUA in development of cardiovascular disease at early stage; and suggest to jointly consider the interactions of SUA with other risk factors in prevention of heart disease.

Acknowledgments

We thank all subjects for participating in this study.

Author Contributions

Conceived and designed the experiments: JL, LQ. Performed the experiments: JL, YL, NZ, FT, JZ, CZ, LQ. Analyzed the data: JL, LQ. Contributed reagents/materials/analysis tools: JL, LQ. Wrote the paper: JL, LQ. Submitted the revised version of the manuscript: JL, LQ. Answered queries from editor and readers: JL, LQ.
References

1. Forman JP, Choi H, Curhan GC (2009) Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 169: 153–162.
2. Liang J, Xue Y, Zou C, Zhang T, Song H, et al. (2009) Serum uric acid and prehypertension among Chinese adults. Journal of Hypertension 27:1761-1765.
3. Fei Teng, Ruihua Zhu, Caiyan Zou, Ying Xue, Manqing Yang, et al. (2010) Interaction Between Serum Uric Acid and Triglycerides in relation to Blood Pressure. Journal of Human Hypertension 12: 31–37.
4. Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, et al. (2007) Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 192: 131–137.
5. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH (2009) Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 61: 225–232.
6. Mankovsky B, Kurashvili R, Sadikot S (2010): Is serum uric acid a risk factor for atherosclerotic cardiovascular disease? A review of the clinical evidence. Part I. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 4:176–184.
7. Gaglardi AC, Miname MH, Santos RD (2009) Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 202:11–17.
8. Neogi T, Ellison RC, Hunt S, Terkeltaub R, Felson DT, et al. (2009) Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol. 36:378–84.
9. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, et al. (2005) Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 111:3384–3390.
10. Krantz MJ, Long CS, Hosokawa P, Karimkahani E, Dickinson M et al. (2011) Pulse wave velocity and carotid atherosclerosis in White and Latino patients with hypertension. BMC Cardiovasc Disord. 11:11–15.
11. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, et al. (2002) Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 105:1202–1207.
12. Tonnimata H, Hashimoto H, Tanaka H, Matsumoto C, Ohtara M, et al. (2010) Brachial ankle PWV Collaboration Group. Synergistic relationship between changes in pulse wave velocity and changes in the heart rate in middle-aged Japanese adults: a prospective study. J Hypertens. 28:167–174.
13. (2002) Clinical practice guidelines for chronic kidney disease. Evaluation, classification and stratification: Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 39: S46–S75.
14. O’Rourke MF, Pauca A, Jiang X-J (2001) Pulse wave analysis. Br J Clin Pharmacol 51:507–522.
15. Hakoda M, Masunari N, Yamada M, Fujisawa S, Suzuki G, et al. (2005) Serum uric acid concentration as a risk factor for cardiovascular mortality: A long term cohort study of atomic bomb survivors, J Rheumatol 32: 906–912.
16. Meisinger C, Koenig W, Baumert J, Döring A (2008) Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/ KORA cohort study. Arterioscler Thromb Vasc Biol 28:1186–1192.
17. Lin Y, Lai X, Chen G, Xu Y, Huang B, et al. (2011) Association among Serum Uric Acid, Cardiovascular Risk and Arterial Stiffness: A Cross-sectional Study in the Ethnic Minority Group of Fujian province in China. J Endocrinol Invest. 2011 May 30. [Epub ahead of print]
18. Sugawara J, Hayashi K, Yokoi T, Cortez-Cooper MY, DeVan AE, et al. (2005) Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Journal of Human Hypertension 19: 801–806.
19. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, et al. (2010) Arterial stiffness and cardiovascular events: the Framingham Heart study. Circulation 121: 565–571.
20. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, et al. (2007) Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50: 823–830.
21. Lanza GA, Fox K, Crea F (2006) Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol 43:1–16.
22. Palatini P (2007) Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms. Drugs 67: 3–13.
23. Palatini P, Dorigliotti F, Zorzi V, Morimino P, Mazza A, et al. (2006) HARVEST Study Group. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens 24:1873–1880.
24. Tomiyama H, Yamada J, Koji Y, Yambe M, Motohe K, et al. (2007) Heart rate elevation precedes the development of metabolic syndrome in Japanese men: a prospective study. Hypertens Res 30: 417–426.
25. Tsoufas C, Dimiriadiou K, Selmia M, Thomopoulos C, Mihas C, et al. (2007) Low-grade inflammation and hypoiodoproteininaemia as an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J 28:1162–1169.
26. Shen L, Wu W, You B, Gao H, Wang C, et al. (2011) Relationship between pulse wave velocity and carotid atherosclerosis in geriatric people. Cerebrovasc Dis. 32:16–20.
27. Sulikowska B, Johnson RJ, Odrowąż-Sypniewska G, Maniatis J (2011) Uric Acid Renal Vasoconstriction and Erythropoietin Relationship in IgA Nephropathy Revealed by Dopamine-Induced Glomerular Filtration Response. Kidney Blood Press Res. 35:161–166.
28. Tsoufas C, Kyvelos S, Dimiriadiou K, Synoloudis D, Sibrizi S, et al. (2011) The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. J Hum Hypertens 25:554–559.